Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
Nature Publishing Group
MetadataShow full item record
Asim, M. (2017). Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nature Communications, 8 (374)https://doi.org/10.1038/s41467-017-00393-y
Emerging data demonstrate homologous recombination (HR) defects in castration resistant prostate cancers, rendering these tumours sensitive to PARP inhibition. Here, we demonstrate a direct requirement for the androgen receptor (AR) to maintain HR gene expression and HR activity in prostate cancer. We show that PARP-mediated repair pathways are upregulated in prostate cancer following androgen-deprivation therapy (ADT). Furthermore, upregulation of PARP activity is essential for the survival of prostate cancer cells and we demonstrate a synthetic lethality between ADT and PARP inhibition in vivo. Our data suggest that ADT can functionally impair HR prior to the development of castration resistance and that this potentially could be exploited therapeutically using PARP inhibitors in combination with ADT upfront in advanced or high-risk prostate cancer.
This study was supported by the National Cancer Research Institute (National Institute of Health Research (NIHR) Collaborative Study: “Prostate Cancer: Mechanisms of Progression and Treatment (PROMPT)” (grant G0500966/75466). We thank the National Institute for Health Research, Hutchison Whampoa Limited, the Human Research Tissue Bank (Addenbrooke’s Hospital), and Cancer Research UK. This work was funded by a Cancer Research UK program grant (D.N.), the Swedish Research Council (T.H.), AFA insurance (T.H.), Swedish Cancer Society (T.H.), the Swedish Pain Relief Foundation (T.H.), the Torsten and Ragnar Söderberg Foundation (T.H.), AstraZeneca (T.H.) Centre for Clinical Research (CKF) (F.T.), the Västmanland Research Foundation for Cancer in Vasteras (F.T.), the Henning and Ida Persson Research Foundation (F.T.).
European Research Council (268536)
Cancer Research UK (A18796)
External DOI: https://doi.org/10.1038/s41467-017-00393-y
This record's URL: https://www.repository.cam.ac.uk/handle/1810/264747
Attribution 4.0 International
Licence URL: http://creativecommons.org/licenses/by/4.0/